Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.01 Million USD | -43.1% |
| 2022 | 38.68 Million USD | -41.38% |
| 2021 | 65.99 Million USD | 40.17% |
| 2020 | 47.08 Million USD | 64.55% |
| 2019 | 28.61 Million USD | -0.02% |
| 2018 | 28.62 Million USD | 915.08% |
| 2017 | 2.81 Million USD | -7.39% |
| 2016 | 3.04 Million USD | -61.53% |
| 2015 | 7.91 Million USD | -46.78% |
| 2014 | 14.86 Million USD | -38.35% |
| 2013 | 24.11 Million USD | -62.79% |
| 2012 | 64.8 Million USD | -15.68% |
| 2011 | 76.86 Million USD | 1311381.45% |
| 2010 | 5861.00 USD | 50.17% |
| 2009 | 3903.00 USD | -55.36% |
| 2008 | 8743.00 USD | 189.5% |
| 2007 | 3020.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 21.57 Million USD | -2.02% |
| 2024 Q2 | 21.53 Million USD | -0.16% |
| 2023 FY | 22.01 Million USD | -43.1% |
| 2023 Q2 | 36.98 Million USD | -3.37% |
| 2023 Q4 | 22.01 Million USD | -40.37% |
| 2023 Q3 | 36.91 Million USD | -0.17% |
| 2023 Q1 | 38.26 Million USD | -1.08% |
| 2022 Q1 | 65.01 Million USD | -1.49% |
| 2022 Q2 | 64.29 Million USD | -1.1% |
| 2022 Q4 | 38.68 Million USD | -39.29% |
| 2022 FY | 38.68 Million USD | -41.38% |
| 2022 Q3 | 63.72 Million USD | -0.89% |
| 2021 Q4 | 65.99 Million USD | 23.36% |
| 2021 FY | 65.99 Million USD | 40.17% |
| 2021 Q2 | 43.34 Million USD | -2.69% |
| 2021 Q1 | 44.53 Million USD | -5.4% |
| 2021 Q3 | 53.49 Million USD | 23.44% |
| 2020 Q4 | 47.08 Million USD | -2.88% |
| 2020 FY | 47.08 Million USD | 64.55% |
| 2020 Q2 | 28.63 Million USD | 0.08% |
| 2020 Q1 | 28.61 Million USD | -0.0% |
| 2020 Q3 | 48.48 Million USD | 69.3% |
| 2019 FY | 28.61 Million USD | -0.02% |
| 2019 Q1 | 28.6 Million USD | -0.05% |
| 2019 Q3 | 28.6 Million USD | -0.02% |
| 2019 Q2 | 28.6 Million USD | 0.01% |
| 2019 Q4 | 28.61 Million USD | 0.03% |
| 2018 Q3 | 28.63 Million USD | 1279.4% |
| 2018 Q1 | 2.78 Million USD | -1.4% |
| 2018 FY | 28.62 Million USD | 915.08% |
| 2018 Q2 | 2.07 Million USD | -25.31% |
| 2018 Q4 | 28.62 Million USD | -0.07% |
| 2017 Q4 | 2.81 Million USD | -7.86% |
| 2017 FY | 2.81 Million USD | -7.39% |
| 2017 Q3 | 3.06 Million USD | 2.34% |
| 2017 Q2 | 2.99 Million USD | -0.66% |
| 2017 Q1 | 3.01 Million USD | 0.0% |
| 2016 FY | 3.04 Million USD | -61.53% |
| 2015 FY | 7.91 Million USD | -46.78% |
| 2014 FY | 14.86 Million USD | -38.35% |
| 2013 FY | 24.11 Million USD | -62.79% |
| 2013 Q4 | 24.11 Million USD | -48.99% |
| 2013 Q3 | 47.27 Million USD | -3.58% |
| 2013 Q2 | 49.03 Million USD | 0.14% |
| 2013 Q1 | 48.96 Million USD | -24.44% |
| 2012 FY | 64.8 Million USD | -15.68% |
| 2012 Q4 | 64.8 Million USD | 2.8% |
| 2012 Q3 | 63.04 Million USD | -7.5% |
| 2012 Q2 | 68.15 Million USD | -3.26% |
| 2012 Q1 | 70.44 Million USD | -18.75% |
| 2011 FY | 76.86 Million USD | 1311381.45% |
| 2011 Q4 | 86.71 Million USD | 2.3% |
| 2011 Q3 | 84.75 Million USD | 2.43% |
| 2011 Q2 | 82.74 Million USD | 7.65% |
| 2011 Q1 | 76.86 Million USD | 1785.08% |
| 2010 Q1 | 5861.00 USD | -35.43% |
| 2010 Q2 | 165 Thousand USD | 2715.22% |
| 2010 Q3 | 165 Thousand USD | 0.0% |
| 2010 Q4 | 4.07 Million USD | 2371.26% |
| 2010 FY | 5861.00 USD | 50.17% |
| 2009 FY | 3903.00 USD | -55.36% |
| 2009 Q4 | 9077.00 USD | -96.98% |
| 2009 Q3 | 300.4 Thousand USD | 7425.18% |
| 2009 Q2 | 3992.00 USD | 2.28% |
| 2009 Q1 | 3903.00 USD | 341.02% |
| 2008 Q1 | 8743.00 USD | -59.11% |
| 2008 Q2 | 3702.00 USD | -57.66% |
| 2008 Q4 | 885.00 USD | -80.56% |
| 2008 FY | 8743.00 USD | 189.5% |
| 2008 Q3 | 4553.00 USD | 22.99% |
| 2007 Q2 | 55.75 Thousand USD | 0.0% |
| 2007 Q3 | 44.6 Thousand USD | -20.01% |
| 2007 Q4 | 21.38 Thousand USD | -52.06% |
| 2007 FY | 3020.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -952933.55% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1024.257% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -108.595% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3887.371% |
| Rebus Holdings, Inc. | 5000.00 USD | -440201.5% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 83.093% |
| Qrons Inc. | 420.00 USD | -5241584.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2756.711% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 21.217% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -4481.158% |
| Skye Bioscience, Inc. | 11.94 Million USD | -84.375% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 43.329% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -204.928% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -28732.903% |
| SQZ Biotechnologies Company | 107.18 Million USD | 79.461% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1437.331% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -30322.269% |
| Mesoblast Limited | 667.9 Million USD | 96.704% |
| Genus plc | 1.02 Billion USD | 97.86% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1520.718% |
| Pharming Group N.V. | 462.85 Million USD | 95.244% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -564.503% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -4311.494% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -3411.176% |
| ContraFect Corporation | 20.67 Million USD | -6.461% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -5539.598% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -5660.44% |
| IMV Inc. | 31.33 Million USD | 29.74% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -430.993% |
| MultiCell Technologies, Inc. | 126.22 USD | -17441727.761% |
| ONE Bio Corp. | 70.08 Million USD | 68.588% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2242.804% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 82.869% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -4999.458% |
| Q BioMed Inc. | 3.51 Million USD | -526.226% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 37.42% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -8325.952% |
| Biomind Labs Inc. | 73.81 Thousand USD | -29723.047% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.067% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1419.493% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 26.653% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -701.617% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3102.258% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -745.694% |
| GB Sciences, Inc. | 103.44 Thousand USD | -21182.53% |
| Alpha Cognition Inc. | 2.45 Million USD | -797.779% |
| HST Global, Inc. | 1526.00 USD | -1442565.465% |
| CSL Limited | 38.02 Billion USD | 99.942% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2128.321% |
| Halberd Corporation | 10.13 Thousand USD | -217204.067% |
| Enzolytics Inc. | 361.7 Million USD | 93.914% |
| Agentix Corp. | 261.39 Thousand USD | -8322.245% |
| Resverlogix Corp. | 8.11 Million USD | -171.289% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1072.337% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.515% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 53.849% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -3341.705% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -96537.878% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -146.002% |
| AVAX Technologies, Inc. | 7.37 Million USD | -198.422% |
| Zenith Capital Corp. | 7410.00 USD | -296999.528% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.35% |
| Ember Therapeutics, Inc. | 184.00 USD | -11964614.674% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -6741.101% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -8323.147% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2272.414% |
| Kadimastem Ltd | 2.3 Million USD | -855.482% |
| Helix BioMedix, Inc. | 3.02 Million USD | -627.75% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 58.226% |
| BioStem Technologies, Inc. | 14.56 Million USD | -51.199% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -38459.349% |
| LadRx Corporation | 2.3 Million USD | -853.908% |
| Cell Source, Inc. | 195.17 Thousand USD | -11179.89% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6125.683% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6125.683% |
| NovAccess Global Inc. | 62.24 Thousand USD | -35266.719% |
| Affymax, Inc. | 7.44 Million USD | -195.782% |
| Itoco Inc. | 1.4 Million USD | -1472.424% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -22914.599% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -20668.939% |
| Mobile Lads Corp. | 52.00 USD | -42336582.692% |
| CytoDyn Inc. | 11.13 Million USD | -97.693% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -15298.172% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -123026.818% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -5611.214% |
| SYBLEU INC | 330.46 Thousand USD | -6561.787% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -5277.111% |
| International Stem Cell Corporation | 5.39 Million USD | -308.443% |
| Bioxytran, Inc. | 137.63 Thousand USD | -15894.911% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -46.749% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -32.789% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -27767.184% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2446.046% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -192.87% |
| Neutra Corp. | 2851.00 USD | -772087.829% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 32.065% |
| PureTech Health plc | 693.97 Million USD | 96.828% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -172.765% |
| IXICO plc | 15.84 Million USD | -38.95% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -165.818% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 78.693% |
| CSL Limited | 38.02 Billion USD | 99.942% |
| Cellectis S.A. | 333.99 Million USD | 93.409% |